EGFR and non-small cell lung carcinoma: The AURA‐3 clinical trial demonstrated that second‐line osimertinib had significantly greater efficacy than pemetrexed plus platinum‐based therapy in advanced‐stage T790M‐mutated NSCLC during treatment with first‐line EGFR TKIs such as gefitinib, erlotinib, and afatinib.7